ClinicalTrials.gg
RecruitingNCT06844643DPCASPAUpdated Apr 13, 2026

The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study

An observational study in Axial Spondyloarthritis and Ankylosing Spondylitis (AS), sponsored by China-Japan Friendship Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-13.

Primary conditionSpondylitis, AnkylosingRegistry: Axial SpondyloarthritisReclassifiedWhy we changed it
Registry
Axial Spondyloarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Spondylitis, Ankylosing
Why
  1. The study's listed conditions name Spondylitis, Ankylosing, a narrower term within Axial Spondyloarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by China-Japan Friendship Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
2,250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Spondylitis, Ankylosing with a site in China — 20 open to participants now, 23 under way, 4 of them phase 3. Spondylitis, Ankylosing · China.

Planned enrollment
3rd of 15
2,250 · median 400
Started
2025
with 9 others
Observational
15 of 77
7 open now
Primary completion
2030-12
later than 22 of 22 live
Registered
60th of 77
by date
Lead sponsor
4 of 77
China-Japan Friendship Hospital

Among the 77 studies in Spondylitis, Ankylosing with a site in China, this one is the 3rd largest by planned enrollment of the 15 observational ones that give a count, is one of 10 that started in 2025, is one of 15 observational ones, reaches primary completion later than 22 of the 22 other live ones, and was the 60th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

20 of the 77 studies in Spondylitis, Ankylosing with a site in China are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Spondylitis, Ankylosing with a site in China, or all of them as a file.
02

Study summary

An observational, ambispective cohort to learn about the disease progression of axial spondyloarthritis (axSpA) according to the changes from baseline in measures of disease activity, function, and imaging.

Read the detailed description

This is an observational cohort study of Chinese patients (≥18 years of age) diagnosed with axSpA. Patients are followed at 4-6 month intervals. Data will be collected at baseline and at every follow-up time points. Primary outcomes are the structural damage measured with imaging(Conventional radiography, low-dose CT and MRI) and the disease activity measured with the Ankylosing Spondylitis Disease Activity Scale (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Secondary outcomes are inflammatory markers, Bath ankylosing spondylitis functional index (BASFI) and Bath ankylosing spondylitis metrology index (BASMI).

03

Conditions studied

  • Axial Spondyloarthritis
  • Ankylosing Spondylitis (AS)

Browse trials for

04

In context

Spondylitis, Ankylosing Reclassified

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

This study's planned enrollment of 2,250 is above the median of 201 across 216 observational studies indexed under Spondylitis, Ankylosing.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

China-Japan Friendship Hospital is the lead sponsor of 179 studies on the registry; 112 are open to participants now.

Compared within Spondylitis, Ankylosing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Axial Spondyloarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with axial spondyloarthritis

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older
  • Diagnosis of axial spondyloarthritis (axSpA) according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria

Exclusion criteria

Exclusion Criteria:

  • Presence of severe, unstable medical conditions that may interfere with the study assessments, including but not limited to:

End-stage renal disease ( \< 30 mL/min/1.73m²) Severe cardiovascular disease Active or malignancy requiring ongoing treatment

  • Current diagnosis of schizophrenia, other psychotic disorders, severe cognitive impairment, or epilepsy with recurrent uncontrolled seizures, which, in the opinion of the investigator, may impair the ability to provide or comply with follow-up visits.
  • Pregnant or lactating women
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
2,250 participants (estimated)
Patient registry
No
07

What researchers measure

Primary outcomes

  1. BASFI

    The Bath Ankylosing Spondylitis Functional Index (BASFI) is a self-administered instrument comprising 10 items. The first 8 items assess functional activities (e.g., bending, reaching, climbing), while items 9 and 10 assess the patient's ability to cope with daily life and the impact of morning stiffness, respectively. Each item is scored on a 10 cm visual analog scale (or numerical rating scale), and the final score is the mean of the 10 items, ranging from 0 (best function) to 10 (worst function)

    Time frame: From enrollment to 16 weeks, 28 weeks, 1 year; after 1year on a an average of 6 months until study completion.

  2. Modified stoke ankylosing spondylitis spinal score (mSASSS)

    The mSASSS is a valid and widely used method for assessing radiographic progression in AS, correlating with worsening measures of disease signs and symptoms, spinal mobility and physical function.

    Time frame: 2-year interval

  3. Anterior uveitis

    The occurrence of anterior uveitis episodes during the disease course in patients with axSpA

    Time frame: From enrollment to 16 weeks, 28 weeks, 1 year; after 1year on a an average of 6 months until study completion.

Secondary outcomes

  1. ASDAS-CRP

    ASDAS-CRP=0.12 x back pain+0.06 x duration of morning stifness +0.11 x patient global+0.07 x peripheral pain/swelling +0.58xIn(CRP+1) The result of the calculation is the ASDAS-CRP score, which is used to classify the disease activity level. Generally, a score of \<1.3 indicates inactive disease, 1.3 - 2.1 indicates low disease activity, 2.1 - 3.5 indicates moderate disease activity, and \>3.5 indicates high disease activity.

    Time frame: From enrollment to 16 weeks, 28 weeks, 1 year; after 1year on a an average of 6 months until study completion.

  2. ASDAS-ESR

    ASDAS-ESR=0.08 x back pain +0.07 x duration of morning stiffness + 0.11 x patient global + 0.09 x peripheral pain/swelling +0.29x√(ESR) The calculated score is used to determine the disease activity level. Typically, a score of \<1.3 suggests inactive disease, 1.3 - 2.1 indicates low disease activity, 2.1 - 3.5 represents moderate disease activity, and \>3.5 means high disease activity.

    Time frame: From enrollment to 16 weeks, 28 weeks, 1 year; after 1year on a an average of 6 months until study completion.

  3. BASDAI

    BASDAI is a validated self assessment tool used to determine disease activity i. Utilizing a Visual Analog Scale (VAS) of 0-10 (0=none and 10=very severe) participant's answered 6 questions measuring discomfort, pain and fatigue. The final BASDAI score averages the individual assessments for a final score range of 0-10.

    Time frame: From enrollment to 16 weeks, 28 weeks, 1 year; after 1year on a an average of 6 months until study completion.

  4. BASMI

    The Bath Ankylosing Spondylitis Metrology Index (BASMI) is a composite index derived from five clinical measurements of spinal and hip mobility: cervical rotation, tragus-to-wall distance, lumbar side flexion, lumbar flexion (modified Schober), and intermalleolar distance . Each component is scored on a scale from 0 to 10, and the total score (0-10, with 10 indicating the most severe impairment) is the mean of these five scores.

    Time frame: From enrollment to 16 weeks, 28 weeks, 1 year; after 1year on a an average of 6 months until study completion.

  5. The Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system.

    The Spondyloarthritis Research Consortium of Canada (SPARCC) developers have created the SPARCC MRI scoring methods to assess inflammatory activity in patients with SpA.

    Time frame: From enrollment to 16 weeks,1 year; after 1year on a an average of 6 months until study completion.

Other outcomes

  1. CT Syndesmophyte Score

    The CT Syndesmophyte Score (CTSS) was developed for the assessment of syndesmophytes on LDCT images.

    Time frame: 2-year interval

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Dec 2030, 69 months after the start.

Of 47 non-industry observational studies under Spondylitis, Ankylosing, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 201. This study's planned 69 months is close to that.

Counting every sponsor, half of 80 studies reached it within 47 months; a quarter within 27 and three quarters within 116.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2025
First posted
Feb 25, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Dec 1, 2030
CompletionEst.
Dec 1, 2030
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06844643
Responsible party
Weiping Kong (Professor, China-Japan Friendship Hospital) — Principal investigator
First posted
Feb 25, 2025
Start date
Mar 1, 2025
Primary completion
Dec 1, 2030 (estimated)
Completion
Dec 1, 2030 (estimated)
Last update
Apr 13, 2026

Study contacts

weiping kong
Contact
kongweiping75@126.com
0086-10-13611038252

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion